Author: [AUTHOR] Published on 8/1/2019 12:00:00 AM
Rodrigo Cristofoletti, MSc, PhD, Research Assistant Professor, Center for Pharmacometrics and Systems Pharmacology in Lake Nona, University of Florida, Orlando, FL
Since graduating from University of Sao Paulo with a BSc in Pharmaceutical Sciences, Dr. Cristofoletti has been an avid reader of Clinical Pharmacology & Therapeutics. He finally became a member of ASCPT after making a career shift from the regulatory field to academia. He was referred to ASCPT by the Associate Director of the Center for Pharmacometrics and Systems Pharmacology (CPSP) at the University of Florida, Dr. Stephan Schmidt. His favorite aspect of his membership in the Society is the ability to volunteer. He was very glad to join the ASCPT Webinar Committee. He also sees his new role on the Committee as a wonderful opportunity for networking.
In Dr. Cristofoletti's view, ASCPT has been an important player/stakeholder in advancing pharmacology, translational medicine, and therapeutics for the benefit of patients and society. He believes ASCPT helps forge a patient‐centric mindset for the field. He also believes that ASCPT unifies therapeutic disciplines, convening clinical pharmacologists in academia, industry, and regulatory bodies to leverage their diverse expertise and foster innovation in an inclusive and collaborative environment.
The Therapeutic Equivalence Department of Anvisa has been Dr. Cristofoletti's place of employment for the last 14 years. While there, he has had the chance to review results from countless BE, BA, drug–drug interaction, food effect, and phase I studies. His job within Anvisa helps in building scientific foundations for generic policies within Brazilian jurisdiction. In June, Dr. Cristofoletti joined the CPSP at the University of Florida. Here, he is teaming up with other scientists to conduct applied research proximal to clinical trials and clinical practice oriented toward problem‐solving through quantitative analysis, drug‐disease modeling/simulation, and clinical trial design. In his new professional home, he looks forward to working on virtual bioequivalence trials to guide formulation and development. He also looks forward to investigating the potential implications of the altered gastrointestinal tracts as a consequence of systemic disease and its impact on oral absorption of poorly soluble and/or poorly permeable compound. He will also be working on integrated proteomics/in vitro–in vivo extrapolation/physiologically based model‐informed approach to investigate tissue distribution of antimicrobials.
Dr. Cristofoletti has been a member of ASCPT since 2017.
